Oragenics and BRAINBox Partner to Advance Concussion Diagnosis and Treatment

Oragenics, Inc. has announced a strategic partnership with BRAINBox Solutions to develop an innovative "trigger-to-treat" platform for mild traumatic brain injuries (mTBI), commonly known as concussions. This collaboration integrates BRAINBox’s AI-driven diagnostic technology with Oragenics’ ONP-002, a novel intranasal therapeutic designed to reduce brain injury effects and promote recovery. Together, they aim to transform TBI care by enabling early detection, predictive prognosis, and targeted treatment.

“This partnership is a major step forward in concussion management,” said Janet Huffman, Interim CEO of Oragenics. “By combining BRAINBox’s diagnostic platform with our therapeutic candidate, we can improve patient outcomes and enhance clinical trial precision.” With over 5 million concussions occurring annually in the U.S., this collaboration could redefine concussion treatment, setting new standards for rapid intervention and personalized care.